Diabetes Mellitus and Heart Failure
- PMID: 28526183
- DOI: 10.1016/j.amjmed.2017.04.010
Diabetes Mellitus and Heart Failure
Abstract
Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of heart failure in diabetes is very high, and the prognosis for patients with heart failure is worse in those with diabetes than in those without diabetes. Experimental data suggest that various mechanisms contribute to the impairment in systolic and diastolic function in patients with diabetes, and there is an increased recognition that these patients develop heart failure independent of the presence of coronary artery disease or its associated risk factors. In addition, current clinical data demonstrated that treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin reduced hospitalization for heart failure in patients with type 2 diabetes mellitus and high cardiovascular risk. This review article summarizes recent data on the prevalence, prognosis, pathophysiology, and therapeutic strategies to treat patients with diabetes and heart failure.
Keywords: Cardiac function; Ejection fraction; Heart failure; Sodium glucose cotransporter 2; Type 2 diabetes mellitus.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Diabetes Mellitus and Heart Failure.Am J Cardiol. 2017 Jul 1;120(1S):S37-S47. doi: 10.1016/j.amjcard.2017.05.014. Epub 2017 May 30. Am J Cardiol. 2017. PMID: 28606342 Review.
-
Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.J Diabetes Complications. 2016 Mar;30(2):189-91. doi: 10.1016/j.jdiacomp.2015.10.015. Epub 2015 Oct 26. J Diabetes Complications. 2016. PMID: 26632087 No abstract available.
-
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Cardiovasc Diabetol. 2016 Apr 4;15:57. doi: 10.1186/s12933-016-0381-x. Cardiovasc Diabetol. 2016. PMID: 27044332 Free PMC article. Clinical Trial.
-
EMPA-REG OUTCOME: The Cardiologist's Point of View.Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006. Am J Med. 2017. PMID: 28526181
-
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.Am J Med. 2017 Jun;130(6S):S30-S39. doi: 10.1016/j.amjmed.2017.04.009. Am J Med. 2017. PMID: 28526184 Review.
Cited by
-
Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies.Drug Des Devel Ther. 2024 Jul 31;18:3337-3360. doi: 10.2147/DDDT.S468147. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39100221 Free PMC article. Review.
-
Efficacy of traditional Chinese medicine on diabetic cardiomyopathy in animal models: a systematic review and meta-analysis.Front Pharmacol. 2023 Sep 28;14:1253572. doi: 10.3389/fphar.2023.1253572. eCollection 2023. Front Pharmacol. 2023. PMID: 37849730 Free PMC article.
-
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.Diabetologia. 2018 Aug;61(8):1724-1733. doi: 10.1007/s00125-018-4642-y. Epub 2018 May 30. Diabetologia. 2018. PMID: 29850922 Free PMC article. Clinical Trial.
-
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30291106 Free PMC article.
-
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.Int J Med Sci. 2022 Jun 21;19(7):1118-1121. doi: 10.7150/ijms.72772. eCollection 2022. Int J Med Sci. 2022. PMID: 35919809 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical